Manejo de Sindrome de Liberação de Citocinas em pacientes adultos e pediátricos
DOI:
https://doi.org/10.46765/2675-374X.2022v3n2p163Palavras-chave:
cytokine release syndrome. CRS. CAR T complications. Anti IL 6. Tocilizumab. Toxicity.Resumo
Chimeric Antigen Receptor (CAR) T cell therapy has demonstrated efficacy in B cell malignances. However, the treatment is not harmless and, in some patients, can lead to a fatal endpoint. For this reason, the knowledge and the early recognition and management of the side effects related to CAR-T cell therapy for the multidisciplinary team is essential. In this article, we have summarized the current recommendations for identification, gradation and management of cytokine release syndrome related to CAR-T cell therapy.
Downloads
Publicado
23/11/2022
Como Citar
GARCIA, J. L., & Rodrigues Kerbauy, F. . (2022). Manejo de Sindrome de Liberação de Citocinas em pacientes adultos e pediátricos. JBMTCT, 3(2), 163. https://doi.org/10.46765/2675-374X.2022v3n2p163
Edição
Seção
Artigos
Licença
Copyright (c) 2022 JBMTCT
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
